Provided herein are compositions and methods for the treatment and prevention of cancer, including melanoma.

Provided herein are compositions and methods for the treatment and prevention of cancer, including melanoma.

This disclosure relates to small molecule inhibitors of paxillin and paxillin binding, and related compositions and methods of treatment.

This disclosure relates to small molecule inhibitors of paxillin and paxillin binding, and related compositions and methods of treatment.

The present invention describes fluorene derivatives substituted by electron-transporting groups, especially for use as triplet matrix materials in electronic devices. The invention further relates to a process for preparing the compounds of the invention and to electronic devices comprising these.

The present invention describes fluorene derivatives substituted by electron-transporting groups, especially for use as triplet matrix materials in electronic devices. The invention further relates to a process for preparing the compounds of the invention and to electronic devices comprising these.

Disclosed herein are certain 4-arylquinazoline derivatives of Formula (I) that are methionine adenosyltransferase 2A (MAT2A) inhibitors. Also disclosed are pharmaceutical compositions comprising such compounds and methods of treating diseases treatable by inhibition of MAT2A such as cancer, including cancers characterized by reduced or absence of methylthioadenosine phosphorylase (MTAP) activity.

##STR00001##

This disclosure provides methods for the treatment of disease by administering pharmaceutical compounds. In particular, the disclosure relates to the treatment to improve memory or cognition, or to treat a memory or cognitive disorder, or to treat cognitive symptoms of a disease or condition by administering a T-type calcium channel antagonist.

This disclosure provides methods for the treatment of disease by administering pharmaceutical compounds. In particular, the disclosure relates to the treatment to improve memory or cognition, or to treat a memory or cognitive disorder, or to treat cognitive symptoms of a disease or condition by administering a T-type calcium channel antagonist.

The present invention relates to saturated-ring-fused dihydropyrimidinone or dihydrotriazinone compounds, or pharmaceutically acceptable salts having RORγ antagonist activity, pharmaceutical compositions comprising the same, and pharmaceutical use thereof. A compound of Formula [I] or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same, and pharmaceutical use thereof are provided:

##STR00001##

wherein each substituent is defined as defined in the description.